PURPOSE: To compare the genetic relationship between cyclin D1-positive and cyclin D1-negative mantle cell lymphomas (MCLs) and to determine whether specific genetic alterations may add prognostic information to survival prediction based on the proliferation signature of MCLs. PATIENTS AND METHODS: Seventy-one cyclin D1-positive and six cyclin D1-negative MCLs previously characterized by gene expression profiling were examined by comparative genomic hybridization (CGH). RESULTS: Cyclin D1-negative MCLs were genetically characterized by gains of 3q, 8q, and 15q, and losses of 1p, 8p23-pter, 9p21-pter, 11q21-q23, and 13q that were also the most common alterations in conventional MCLs. Parallel analysis of CGH aberrations and locus-specific gene expression profiles in cyclin D1-positive patients showed that chromosomal imbalances had a substantial impact on the expression levels of the genes located in the altered regions. The analysis of prognostic factors revealed that the proliferation signature, the number of chromosomal aberrations, gains of 3q, and losses of 8p, 9p, and 9q predicted survival of MCL patients. A multivariate analysis showed that the gene expression-based proliferation signature was the strongest predictor for shorter survival. However, 3q gains and 9q losses provided prognostic information that was independent of the proliferative activity. CONCLUSION: Cyclin D1-positive and -negative MCLs share the same secondary genetic aberrations, supporting the concept that they correspond to the same genetic entity. The integration of genetic information on chromosome 3q and 9q alterations into a proliferation signature-based model may improve the ability to predict survival in patients with MCL.
PURPOSE: To compare the genetic relationship between cyclin D1-positive and cyclin D1-negative mantle cell lymphomas (MCLs) and to determine whether specific genetic alterations may add prognostic information to survival prediction based on the proliferation signature of MCLs. PATIENTS AND METHODS: Seventy-one cyclin D1-positive and six cyclin D1-negative MCLs previously characterized by gene expression profiling were examined by comparative genomic hybridization (CGH). RESULTS:Cyclin D1-negative MCLs were genetically characterized by gains of 3q, 8q, and 15q, and losses of 1p, 8p23-pter, 9p21-pter, 11q21-q23, and 13q that were also the most common alterations in conventional MCLs. Parallel analysis of CGH aberrations and locus-specific gene expression profiles in cyclin D1-positive patients showed that chromosomal imbalances had a substantial impact on the expression levels of the genes located in the altered regions. The analysis of prognostic factors revealed that the proliferation signature, the number of chromosomal aberrations, gains of 3q, and losses of 8p, 9p, and 9q predicted survival of MCLpatients. A multivariate analysis showed that the gene expression-based proliferation signature was the strongest predictor for shorter survival. However, 3q gains and 9q losses provided prognostic information that was independent of the proliferative activity. CONCLUSION:Cyclin D1-positive and -negative MCLs share the same secondary genetic aberrations, supporting the concept that they correspond to the same genetic entity. The integration of genetic information on chromosome 3q and 9q alterations into a proliferation signature-based model may improve the ability to predict survival in patients with MCL.
Authors: A Cuneo; R Bigoni; G M Rigolin; M G Roberti; A Bardi; N Piva; R Milani; F Bullrich; M L Veronese; C Croce; F Birg; H Döhner; A Hagemeijer; G Castoldi Journal: Blood Date: 1999-02-15 Impact factor: 22.113
Authors: O Monni; R Oinonen; E Elonen; K Franssila; L Teerenhovi; H Joensuu; S Knuutila Journal: Genes Chromosomes Cancer Date: 1998-04 Impact factor: 5.006
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: S Beà; M Ribas; J M Hernández; F Bosch; M Pinyol; L Hernández; J L García; T Flores; M González; A López-Guillermo; M A Piris; A Cardesa; E Montserrat; R Miró; E Campo Journal: Blood Date: 1999-06-15 Impact factor: 22.113
Authors: Luis Hernández; Silvia Beà; Magda Pinyol; German Ott; Tiemo Katzenberger; Andreas Rosenwald; Francesc Bosch; Armando López-Guillermo; Jan Delabie; Dolors Colomer; Emili Montserrat; Elías Campo Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Margit Schraders; Rolph Pfundt; Huub M P Straatman; Irene M Janssen; Ad Geurts van Kessel; Eric F P M Schoenmakers; Johan H J M van Krieken; Patricia J T A Groenen Journal: Blood Date: 2004-10-21 Impact factor: 22.113
Authors: M Pinyol; F Cobo; S Bea; P Jares; I Nayach; P L Fernandez; E Montserrat; A Cardesa; E Campo Journal: Blood Date: 1998-04-15 Impact factor: 22.113
Authors: Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M Lachel; Karen Deffenbacher; Timothy C Greiner; Julie M Vose; Sharathkumar Bhagavathi; Louis M Staudt; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Timothy W McKeithan; Wing C Chan Journal: Blood Date: 2012-04-05 Impact factor: 22.113
Authors: Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez Journal: Haematologica Date: 2012-02-07 Impact factor: 9.941
Authors: Ana Mozos; Cristina Royo; Elena Hartmann; Daphne De Jong; Cristina Baró; Alexandra Valera; Kai Fu; Dennis D Weisenburger; Jan Delabie; Shih-Sung Chuang; Elaine S Jaffe; Carmen Ruiz-Marcellan; Sandeep Dave; Lisa Rimsza; Rita Braziel; Randy D Gascoyne; Francisco Solé; Armando López-Guillermo; Dolors Colomer; Louis M Staudt; Andreas Rosenwald; German Ott; Pedro Jares; Elias Campo Journal: Haematologica Date: 2009-11 Impact factor: 9.941
Authors: Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo Journal: Virchows Arch Date: 2015-08-23 Impact factor: 4.064
Authors: Itziar Salaverria; Cristina Royo; Alejandra Carvajal-Cuenca; Guillem Clot; Alba Navarro; Alejandra Valera; Joo Y Song; Renata Woroniecka; Grzegorz Rymkiewicz; Wolfram Klapper; Elena M Hartmann; Pierre Sujobert; Iwona Wlodarska; Judith A Ferry; Philippe Gaulard; German Ott; Andreas Rosenwald; Armando Lopez-Guillermo; Leticia Quintanilla-Martinez; Nancy L Harris; Elaine S Jaffe; Reiner Siebert; Elias Campo; Sílvia Beà Journal: Blood Date: 2012-12-18 Impact factor: 22.113
Authors: Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo Journal: Blood Date: 2008-11-04 Impact factor: 22.113
Authors: Heike Stöcklein; Grit Hutter; Jörg Kalla; Elena Hartmann; Yvonne Zimmermann; Tiemo Katzenberger; Patrick Adam; Ellen Leich; Sylvia Höller; Hans Konrad Müller-Hermelink; Andreas Rosenwald; German Ott; Martin Dreyling Journal: J Hematop Date: 2008-07-05 Impact factor: 0.196